XML 24 R16.htm IDEA: XBRL DOCUMENT
v3.25.2

Stock-based Compensation | 6 Months Ended
--- | ---
Jun. 30, 2025
Share-based Payment Arrangement [Abstract] |
Stock-based Compensation | 7. Stock-based Compensation 2006 Equity Incentive Plan and Amendment to 2006 Plan Private CalciMedica adopted an equity incentive plan in 2006 (“2006 Plan”) that provides for the issuance of common stock to employees, non-employee directors and consultants. Recipients of incentive stock options are eligible to purchase common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The 2006 Plan provides for the grant of incentive stock options, non-statutory stock options and stock purchase rights. The maximum contractual term of options granted under the 2006 Plan is ten years. The options generally vest 25% on the first anniversary of the grant date, with the balance vesting ratably over the following 36 months. In connection with the Merger, the Company assumed the 2006 Plan and all stock options issued and outstanding under the 2006 Plan. 2023 Equity Incentive Plan The Company adopted the 2023 Equity Incentive Plan (the “2023 Plan”), which became effective at the closing of the Merger and replaced its 2020 Equity Incentive Plan (the “2020 Plan”) on the effective date of the Merger. As of the effective date of the Merger, there were 1,000,000 shares of the Company’s common stock available for grant under the 2023 Plan. In addition, the share reserve is subject to annual increases each January 1 for the first ten years following approval of the 2023 Plan of up to 5% of shares of the Company’s common stock outstanding (or a lesser number determined by the Company’s board of directors). Effective January 1, 2024, the shares reserved for issuance under the 2023 Plan was increased by 287,725 shares of the Company’s common stock. Effective March 28, 2024, the Board approved an increase of 1,500,000 shares of the Company’s common stock reserved under the 2023 Plan, which was subsequently approved by the stockholders of the Company on August 27, 2024. As of January 1, 2025 an additional 674,095 shares of the Company’s common stock were added to the plan per the annual increase. On April 23, 2025 the Board approved an increase of 600,000 shares of the Company’s common stock reserved for issuance under the 2023 Plan, which was subsequently approved by the stockholders of the Company on June 24, 2025. As of June 30, 2025, 139,709 shares of the Company’s common stock were available for grant under the 2023 Plan. 2023 Employee Stock Purchase Plan The Company adopted the 2023 Employee Stock Purchase Plan (the “2023 ESPP”) which became effective at the closing of the Merger. As of the effective time of the Merger, there were 65,000 shares of the Company’s common stock reserved for issuance under the 2023 ESPP. In addition, the share reserve is subject to annual increases each January 1 for the first ten years following approval of the 2023 ESPP of the lesser of (i) 1% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, (ii) 195,000 shares of the Company’s common stock, or (iii) such lesser number of shares of the Company’s common stock as determined by the Company’s board of directors. An annual increase of 57,545 and 134,819 shares of the Company’s common stock was automatically added to the share reserve under the 2023 ESPP on January 1, 2024 and 2025, respectively. As of June 30, 2025, 257,364 shares of the Company’s common stock were available for grant under the 2023 ESPP. As of June 30, 2025, no shares have been issued under the 2023 ESPP. The following table summarizes the stock option transactions for the 2023 Plan:
|  | Total Options |  |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term (years) |  |  |  | Aggregate Intrinsic Value (in thousands) |
Outstanding at December 31, 2024 |  |  | 2,824,443 |  |  | $ |  | 5.51 |  |  |  | 8.15 |  |  | $ |  | 316 |
Granted |  |  | 1,994,652 |  |  |  |  | 1.55 |  |  |  | 9.86 |  |  |  |  | 134 |
Cancelled |  |  | (40,000 | ) |  |  |  | 3.71 |  |  |  | — |  |  |  |  | — |
Outstanding at June 30, 2025 |  |  | 4,779,095 |  |  | $ |  | 3.87 |  |  |  | 8.57 |  |  | $ |  | 134 |
Vested and exercisable at June 30, 2025 |  |  | 2,149,098 |  |  | $ |  | 5.04 |  |  |  | 7.67 |  |  | $ |  | 38 |
There were no options exercised and 1,994,652 options granted during the six months ended June 30, 2025. The weighted-average fair value of options granted during the six months ended June 30, 2025 and 2024 was $1.31 and $4.17 per share, respectively. The total fair value of shares vested was $1.6 million and $0.8 million for the six months ended June 30, 2025 and 2024, respectively. As of June 30, 2025, stock-based compensation not yet recognized is $5.6 million, which the Company expects to recognize over an estimated weighted-average term of 2.6 years. The following are the underlying assumptions in Black-Scholes to determine the fair value of the stock option grants for the six months ended June 30, 2025 and 2024:
|  | Six Months Ended June 30,
|  | 2025 |  | 2024
Risk free interest rate |  | 3.49% |  | 2.96%
Expected volatility |  | 101% |  | 89%
Expected term (years) |  | 5.87 |  | 6.08
Expected dividend yield |  | 0% |  | 0%
Restricted Stock Units (“RSU’s”) The fair value of RSU’s is determined on the date of grant based on the market price of the Company’s common stock on that date. The aggregate grant date fair value of RSU’s vested during the six months ended June 30, 2025 was zero. The following table summarizes restricted stock unit activity for the CalciMedica Plans:
|  | Number of Restricted Stock Units |  |  |  | Weighted Average Grant Date Fair Value |
Outstanding at December 31, 2024 |  |  | 40,000 |  |  | $ |  | 3.50 |
Outstanding at June 30, 2025 |  |  | 40,000 |  |  | $ |  | 3.50 |
Vested and exercisable at June 30, 2025 |  |  | — |  |  | $ |  | — |
Stock-based Compensation Expense Stock-based compensation expense recognized for options, RSU’s and Common Stock Warrants granted was as follows (in thousands):
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Research and development |  | $ | 381 |  |  | $ | 190 |  |  | $ | 559 |  |  | $ | 361 |
General and administrative |  |  | 793 |  |  |  | 296 |  |  |  | 1,165 |  |  |  | 539 |
Total stock-based compensation expense |  | $ | 1,174 |  |  | $ | 486 |  |  | $ | 1,724 |  |  | $ | 900 |
Common Stock Reserved for Future Issuance Common stock reserved for future issuance consists of the following at June 30, 2025:
|  | June 30, |
|  | 2025 |
Common stock warrants |  |  | 3,993,784 |
Stock options issued and outstanding |  |  | 4,779,095 |
Restricted stock units outstanding |  |  | 40,000 |
Shares available for issuance under the 2023 Plan |  |  | 139,709 |
Shares available under the 2023 ESPP |  |  | 257,364 |
Total |  |  | 9,209,952 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration